Product Development

Sizing up Ovid’s soticlestat among Dravet therapies

Ovid and Takeda are zeroing in on Dravet syndrome patients for a Phase III trial of soticlestat after Phase II data showed the therapy fared better in the smaller indication than it did in Lennox-Gastaut syndrome.

The readout places